Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06620406 · ClinicalTrials.gov registry record · NA
Synbiotic Therapy for NP-PASC
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT06620406 is a NA study that has completed, run by Columbia University. The registered enrollment target is 36 participants.
The verdict
NCT06620406, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
Gut microbiome dysbiosis has been noted in patients with Post-acute sequelae (PASC) of Severe Acute Respiratory Syndrome-CoronaVirus -2 (SARS-CoV-2). A study performed at Columbia found that plasma levels of the short chain fatty acid (SCFA), butyric acid, remained lower in people with Neuropsychiatric PASC (NP-PASC) than in people with PASC after SAR-CoV-2 infection. Synbiotics improve SCFA levels and are well-tolerated in the general population but have not been studied among people with PASC in the United States. The purpose of this pilot study is to characterize changes in plasma SCFA levels and gut microbiome after treatment with synbiotics and placebo in people with NP-PASC. The intervention will be a mixture of the prebiotic resistant starch and the probiotic Bifidobacterium adolescentis in-vivo selection 1 strain (iVS-1). The placebo will be Maltodextrin.
Interventions
- DIETARY_SUPPLEMENT Maltodextrin
- DIETARY_SUPPLEMENT Synbiotic IVS-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2025-08-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06620406
The ClinicalTrials.gov registry entry for NCT06620406 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Maltodextrin is the first listed.
NCT06620406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06620406 about?
NCT06620406 is a clinical study titled "Synbiotic Therapy for NP-PASC". Gut microbiome dysbiosis has been noted in patients with Post-acute sequelae (PASC) of Severe Acute Respiratory Syndrome-CoronaVirus -2 (SARS-CoV-2). A study performed at Columbia found that plasma levels of the short chain fatty acid (SCFA), butyric acid, remained lower in people with Neuropsychiat...
What is the current status of trial NCT06620406?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2024-12-09. Estimated completion is 2025-08-06.
What interventions are being tested in trial NCT06620406?
The interventions under investigation include: Maltodextrin (DIETARY_SUPPLEMENT), Synbiotic IVS-1 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06620406?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.